Skip to main content

Advertisement

Table 2 Dynamic fluctuation of CTCs in patients according to VEGFR status during follow-up

From: Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients

  CTC1 (baseline) CTC2 (12 weeks) CTC3 (24 weeks) p (CTC1 vs CTC2) p (CTC1 vs CTC3) p (CTC1–CTC3)
Patients with CTCs (CTCsCK+) N (%) 33 (42.8%) 18 (29%) 12 (18.2%) 0.088 0.005 0.015
Mean number of CTCsCK+ (SD; range) 1.5 (1.5; 0–8) 1.7 (8.1; 0–64) 0.5 (1.5; 0–9) 0.019 0.003  
Patients with CTCsCK+VEGFR+) N (%) 23 (69.7%) 7 (38.9%) 5 (41.7%) 0.102 0.317 0.368
Mean number of CTCsCK+VEGFR+ (SD; range) 1.4 (1.5; 0–5) 0.6 (1.05; 0–3) 0.5 (0.8; 0–2) 0.120 0.317  
  1. CTCs: circulating tumor cells; CK: cytokeratin; VEGFR: vascular endothelial growth factor receptor; SD: standard deviation; p: p value